Vaccination of Patients with Metastatic Renal Cancer with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α

Journal of Immunotherapy

Volumn 32, Issue 4, 2009, Pages 424-429

  Hawkins, Robert E ^a,c   MacDermott, Catriona ^a   Shablak, Alaaeldin ^a   Hamer, Caroline ^a   Thistlethwaite, Fiona ^a   Drury, Noel L ^b   Chikoti, Priscilla ^b   Shingler, William ^b   Naylor, Stuart ^b   Harrop, Richard ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5T4 tumor antigen; Immunotherapy; Renal cancer; Vaccine

Indexed keywords

ALPHA INTERFERON; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; CANCER VACCINE; TUMOR ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INDIGESTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; KIDNEY CANCER; LETHARGY; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED;

AGED; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 67449085969     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819d297e     Document Type: Article

References (23)

1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med. 1996;335:865-875.
2. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-17.
3. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20: 289-296.
4. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
5. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295: 2516-2524.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
7. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1998;57:239-246.
8. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
9. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005;93: 670-677.
10. Carsberg CJ, Myers KA, Evans GS, et al. Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane. Cell Sci. 1995;108:2905-2916.
11. Carsberg CJ, Myers KA, Stern PL. Metastasis associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer. 1996;68:84-92.
12. Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902.
13. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66: 867-869.
14. Wrigley E, McGown AT, Rennison J, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5:269-274.
15. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6: 1632-1638.
16. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant non-replicating avipox virus to elicit anti-carci-noembryonic antigen immune responses. J Clin Oncol. 2000; 18:3964-3973.
17. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5:690-699.
18. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;16:3416-3424.
19. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;3:4487-4494.
20. Jocham D, Richter A, Hoffman L, et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363: 594-599.
21. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008;57:977-986.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
23. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double blind phase III trial. Lancet. 2007;370:2130-2131.